Advertisement

Having trouble viewing this email? View in a browser.

You are subscribed to %%list.name%% as %%emailaddr%%. Unsubscribe.

Formulary

Formulary News Capsule

FormularyJournal.com

March 23, 2012

LONG-TERM CARE

Study highlights need to treat female nursing-home patients for vitamin D deficiency

The majority of older women in nursing homes are likely to be deficient in vitamin D during winter months, and those with the lowest levels are at a significantly increased risk of death, according to a study published online February 8, in the Journal of Clinical Endocrinology & Metabolism. » More

Editor's Pick

Teriflunomide: An orally administered disease-modifying drug for the treatment of multiple sclerosis

Teriflunomide is a once-daily, orally administered, disease-modifying drug undergoing FDA review as a potential therapy for patients with relapsing forms of multiple sclerosis (MS).  If approved by FDA, teriflunomide would be one of the first available oral treatments for MS.
» Click here.

CONTINUING EDUCATION

The latest FDA drug approvals: What you need to know

Of the 35 new molecular entities approved by FDA in 2011, 17 are considered groundbreaking because of their potential to make a real difference in the lives of patients.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.

CLINICAL NEWS

Clinical pharmacists can help reduce discrepancies in patient medication histories

Clinical pharmacists were instrumental in reducing errors in patients’ physician-acquired medication histories, according to a study published online on March 13 in the Annals of Pharmacotherapy. » More

Alzheimer’s drugs donepezil, memantine show some benefits in study

A new study of patients with moderate-to-severe Alzheimer’s disease found that extended treatment with donepezil could improve cognition and function for even severe patients; however, experts caution that the benefits of the drug were modest. » More

Heroin may be more effective than methadone for relapsing addicts

Diacetylmorphine, or heroin, may be a more effective treatment than methadone for people with relapsing chronic opioid dependence, according to a study published in the Canadian Medical Association Journal. » More

Ingenol mebutate gel is effective treatment for actinic keratosis, study shows

Ingenol mebutate topical gel (0.015% for face and scalp and 0.05% for trunk and extremities) was effective for treating actinic keratoses, a common precursor to sun-related, squamous cell carcinoma, according to a new study. » More

FDA ACTIONS

FDA approves first Boniva generics to treat or prevent osteoporosis

FDA approved the first generic versions of Boniva (ibandronate) tablets, a once-monthly product to treat or prevent osteoporosis in women after menopause. » More

FDA approves first effervescent osteoporosis treatment in a buffered solution

FDA has approved alendronate sodium (Binosto, EffRx Pharmaceuticals) effervescent tablets, the first effervescent osteoporosis treatment in a buffered solution. » More

DRUG TRENDS

Amneal launches first generic equivalent to Lexapro in liquid form

Amneal Pharmaceuticals has launched escitalopram oxalate oral solution in 5 mg/5 mL strength, the first generic of antianxiety/antidepressant Lexapro (Forest) in liquid form on the market. » More

Survey

In the online New England Journal of Medicine, 2 Canadian doctors disagree with Medicare's 3-year coverage policy of immunosuppressive therapy following kidney transplantation because the annual cost of immunosuppressive therapy is $15,000 to $20,000 but the cost of dialysis after graft failure is substantially higher at $75,000. Should Medicare change its policy of 3-year coverage of immunosuppressive therapy following kidney transplantation to lifelong coverage?

Yes
No

Respond here and see what your colleagues think too.

Want to see the results of our last survey regarding who performs medication therapy management in your health system? Click here.

Twitter  

Follow us on Twitter

Confirm your
e-newsletter subscription click here.

To ensure future delivery of email newsletters from Formulary please take a moment to confirm your subscription by clicking here.
Thank you,
Formulary Staff

Resources

Drug Watch

FDA Actions

Latest News

Medication Safety

Policy Watch

Digital Edition

View current edition

Cover
 
Powered by Modern Medicine Advanstar Medical Communications Group
 

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.